Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Passage BIO, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 51 | 52 | +1 |
| Shares | 32.4M | 32.8M | +369.1K (+1.1%) |
| Value | $21.3M | $33.1M | +$11.8M (+55.2%) |
New holders (8)
Institutions that held Passage BIO, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 67,704 | $68.0K | 0.01% |
| DLK Investment Management, LLC | 64,000 | $64.6K | 0.03% |
| Two Sigma Securities, LLC | 40,327 | $40.7K | 0.00% |
| Scientech Research LLC | 18,853 | $19.0K | 0.02% |
| Susquehanna International Group, LLP | 18,533 | $18.7K | 0.00% |
| Citigroup Inc | 4,798 | $4.85K | 0.00% |
| Simplex Trading, LLC | 2,089 | $2.00K | 0.00% |
| UBS Group AG | 1,059 | $1.07K | 0.00% |
Sold out (7)
Institutions that held Passage BIO, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| BML Capital Management, LLC | 2,058,767 | $1.35M |
| Frazier Life Sciences Management, L.P. | 1,758,219 | $1.16M |
| Squarepoint Ops LLC | 74,046 | $48.7K |
| Tower Research Capital LLC (TRC) | 13,725 | $9.03K |
| D. E. Shaw & Co., Inc. | 10,026 | $6.60K |
| Federated Hermes, Inc. | 511 | $336 |
| US Bancorp | 500 | $329 |